A detailed history of Aigen Investment Management, LP transactions in Novo Cure LTD stock. As of the latest transaction made, Aigen Investment Management, LP holds 12,209 shares of NVCR stock, worth $205,843. This represents 0.04% of its overall portfolio holdings.

Number of Shares
12,209
Previous 35,189 65.3%
Holding current value
$205,843
Previous $602,000 68.44%
% of portfolio
0.04%
Previous 0.12%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$15.61 - $23.34 $358,717 - $536,353
-22,980 Reduced 65.3%
12,209 $190,000
Q2 2024

Aug 09, 2024

BUY
$11.83 - $24.05 $287,610 - $584,703
24,312 Added 223.52%
35,189 $602,000
Q1 2024

May 14, 2024

BUY
$12.42 - $17.29 $135,092 - $188,063
10,877 New
10,877 $170,000
Q3 2023

Nov 13, 2023

BUY
$16.15 - $42.35 $733,742 - $1.92 Million
45,433 New
45,433 $733,000
Q4 2021

Feb 11, 2022

SELL
$75.08 - $121.99 $394,845 - $641,545
-5,259 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$116.17 - $194.55 $610,938 - $1.02 Million
5,259 New
5,259 $611,000
Q2 2021

Aug 10, 2021

SELL
$130.4 - $225.58 $220,376 - $381,230
-1,690 Closed
0 $0
Q1 2021

May 11, 2021

BUY
$124.11 - $190.17 $209,745 - $321,387
1,690 New
1,690 $223,000
Q3 2020

Nov 06, 2020

SELL
$58.05 - $111.31 $1.15 Million - $2.2 Million
-19,774 Closed
0 $0
Q2 2020

Aug 10, 2020

BUY
$57.2 - $74.41 $400,342 - $520,795
6,999 Added 54.79%
19,774 $1.17 Million
Q1 2020

May 08, 2020

SELL
$57.05 - $95.75 $548,592 - $920,732
-9,616 Reduced 42.95%
12,775 $860,000
Q4 2019

Feb 04, 2020

BUY
$68.3 - $93.8 $1.53 Million - $2.1 Million
22,391 New
22,391 $1.89 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.77B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Aigen Investment Management, LP Portfolio

Follow Aigen Investment Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Aigen Investment Management, LP with notifications on news.